183 results on '"Lake, Richard"'
Search Results
2. Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner
3. Mesothelioma survival prediction based on a six-gene transcriptomic signature
4. Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice
5. Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes
6. The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop
7. Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used
8. Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
9. Voluntary exercise in mesothelioma: effects on tumour growth and treatment response in a murine model
10. Correction to: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used
11. Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma
12. Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
13. Supplementary Table 1 from A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions
14. Supplementary Tables 2-3 from A Novel SV40 TAg Transgenic Model of Asbestos-Induced Mesothelioma: Malignant Transformation Is Dose Dependent
15. Data from A Novel SV40 TAg Transgenic Model of Asbestos-Induced Mesothelioma: Malignant Transformation Is Dose Dependent
16. CD4+ T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy
17. Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
18. Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma
19. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action
20. Early clonal expansion of tumor-infiltrating lymphocytes predicts response to immune checkpoint therapy
21. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations
22. Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy
23. PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective
24. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis
25. Temporally restricted activation of IFNβ signaling determines response to immune checkpoint therapy
26. The Control of Carbon Dioxide Emissions from Freight Transportation: A Case Studies Approach
27. Scientific and stakeholder evidence-based assessment:Ecosystem response to floating solar photovoltaics and implications for sustainability
28. Prioritising ecosystem opportunities and threats of floating solar photovoltaics
29. Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?
30. How to Better Understand the Influence of Host Genetics on Developing an Effective Immune Response to Thoracic Cancers
31. Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?
32. A National Transportation Research Organization: Alternatives and Factors
33. Prioritising ecosystem opportunities and threats of floating solar photovoltaics
34. A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers
35. Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy
36. Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
37. Voluntary Exercise in Mesothelioma: Effects on Tumour Growth and Treatment Response in a Murine Model
38. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
39. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
40. Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment
41. Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy.
42. Combination immune checkpoint blockade as an effective therapy for mesothelioma
43. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice
44. Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters
45. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response
46. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
47. Additional file 2: Table S2. of Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
48. Additional file 4: Table S4. of Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
49. Additional file 5: Table S5. of Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
50. Additional file 3: Table S3. of Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.